Lilly, Incyte's baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO
→ Rheumatoid arthritis drug Olumiant — approved for a narrower-than-expected patient population earlier this year to the dismay of its manufacturer Eli Lilly $LLY and Incyte $INCY which had blockbuster dreams for the drug — may be worth its weight in gold if approved for lupus, a disease in which the immune system attacks its host, and has seen a solitary approved treatment in the last 50 years. The companies announced on Thursday that the drug, known chemically as baricitinib, had been granted fast-track status by the FDA for lupus. Two doses of baricitinib, which is also being investigated as a treatment for atopic dermatitis, are currently in Phase III trials in patients with systemic lupus erythematosus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.